Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Sets Up New Research Sites in US, Germany
May 23, 2024
- Otsuka Axes Alzheimer’s Agitation Drug, Cuts Half-Year Profit Outlook
May 23, 2024
- Bridion Generics Now Available; Maruishi to Launch on May 27
May 23, 2024
- Janssen Files Bispecific Teclistamab for MM in Japan
May 23, 2024
- Japan Pharma Market Crosses 11 Trillion Yen in FY2023, Keytruda Triumphs: IQVIA
May 22, 2024
- Biogen Files Tofersen as Japan’s 1st Genetic ALS Drug
May 22, 2024
- Novo to Prioritize Markets for GLP-1 Supply, Touts Massive Lift in Capacity
May 22, 2024
- Japan’s 1st Stelara Biosimilar to Hit Market on May 29
May 22, 2024
- Servier Trains Sight on 50% Oncology Sales Ratio by 2030, Set to Upsize Japan Biz
May 22, 2024
- Asahi Kasai to Integrate Japan and US Pharma Biz by March 2026
May 21, 2024
- BMS’ Reblozyl Now Available in Japan for Anemia in MDS
May 21, 2024
- Sandoz to Take Over Astellas’ Japan MA for Funguard from June-End
May 21, 2024
- Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
- Pfizer Rolls Out Single-Dose Version of COVID-19 Vaccine in Japan
May 20, 2024
- Keytruda Gets Nod for Gastric, Biliary Tract Cancer in Japan
May 20, 2024
- Prevymis Now Approved for CMV Prevention in Organ Transplant Recipients in Japan
May 20, 2024
- Braftovi-Mektovi Combo Broadens Label to Thyroid Cancer: Ono
May 20, 2024
- Amylyx Pulls Out from Japan after ALS Trial Flop
May 20, 2024
- Mitsubishi Tanabe’s Earnings Sink 2-Digits in FY2023 on Backlash from Previous Gilenya Royalties
May 17, 2024
- Eisai to Appoint CEO’s Son for Representative Post in Prelude to Succession
May 17, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…